Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
57.914,36
-4,43%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Canada TSX Antibe Therapeutics Inc (ATE) Antibe Therapeutics Inc (ATE) Notizie

Antibe Therapeutics Inc

ATE
0,295
0,00 (0,00%)
01 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: Toronto
Tipo: Azione
Valuta: CAD

Ultime notizie

Data Ora Fonte Titolo
24/4/202417:15BWAntibe Announces Appointment of Receiver
19/4/202414:00BWAntibe Provides Update on CCAA Proceedings
16/4/202423:00BWAntibe Announces TSX Delisting Review
10/4/202401:00BWAntibe Announces Granting of Initial Order Under Companies'..
09/4/202417:25PRNCACanadian Investment Regulatory Organization Trade Resumption..
09/4/202415:44PRNCASuspension de la négociation par l'Organisme canadien de..
09/4/202415:42PRNCACanadian Investment Regulatory Organization Trading Halt -..
09/4/202413:00BWAntibe to File an Application for an Initial Order Under..
01/4/202413:00BWAntibe Announces FDA Clinical Hold on Otenaproxesul and..
20/3/202412:00BWAntibe to Present Otenaproxesul PK/PD Results at the ASRA..
07/3/202413:00BWAntibe to Present Otenaproxesul PK/PD Results at the..
04/3/202413:00BWAntibe Announces Unfavorable Decision in Arbitration With..
14/2/202413:00BWAntibe Reports Q3 2024 Interim Financial and Operating..
01/2/202413:00BWAntibe Extends Early Warrant Exercise Incentive Program
29/12/202313:00BWAntibe Announces Early Warrant Exercise Incentive Program
12/12/202313:00BWAntibe Therapeutics Announces Amendment to Warrant Terms
13/11/202313:00BWAntibe Reports Q2 2024 Interim Financial and Operating..
09/11/202313:00BWAntibe Reports PK Results of First Clinical Study of..
01/11/202312:00BWAntibe Completes First Clinical Study of Otenaproxesul’s New..
18/10/202313:00BWAntibe Initiates First Clinical Study of Otenaproxesul’s New..
28/9/202313:00BWAntibe Receives Approval to Initiate PK/PD Study of..
08/9/202323:00BWAntibe Announces Results of 2023 Annual Meeting
21/8/202321:23PRNCAToronto Stock Exchange, Antibe Therapeutics Inc., View From..
14/8/202313:00BWAntibe Reports Q1 2024 Interim Financial and Operating..
29/6/202313:30BWAntibe Reports 2023 Year-End Results and Business Highlights
Apertura: Min: Max:
Chiusura: 0,295

La tua Cronologia

TSX
ATE
Antibe Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network